Acquiring Company
Curium Pharma
Acquired Company
Eczacıbaşı-Monrol Nuclear Product (Monrol)
Paris
IstanbulManufacturingBiotechnologyHealth CareManufacturingBiotechnologyHealth CareDescription
Curium Pharma has completed the acquisition of Eczacıbaşı-Monrol Nuclear Products Co. This acquisition enhances Curium's manufacturing capacity for Lutetium-177, expands its geographical footprint, and adds significant R&D capabilities. The deal will help meet rising global demand for isotopes and secure the supply of Curium’s new drug candidates.
Quick answer
Curium Pharma is acquiring Eczacıbaşı-Monrol Nuclear Product (Monrol), announced March 28, 2025. Curium Pharma is based in Paris, Ile-de-France, France.
- How much did Curium Pharma pay for Eczacıbaşı-Monrol Nuclear Product (Monrol)?
- The deal value was not disclosed.
- What does Curium Pharma do?
- Curium is a world leader in nuclear medicine.
- Where are Curium Pharma and Eczacıbaşı-Monrol Nuclear Product (Monrol) based?
- Curium Pharma is based in Paris, Ile-de-France, France. Eczacıbaşı-Monrol Nuclear Product (Monrol) is based in Istanbul, Istanbul, Turkey.
- Who are the decision-makers at Curium Pharma?
- Fundz holds 4 contacts at Curium Pharma. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Manufacturing and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie to acquire Cerevel for $45 per share (April 15, 2025)
- AbbVie acquires Cerevel Therapeutics for $45 per share (March 31, 2025)
- Roquette acquires IFF Pharma Solutions for growth (May 5, 2025)
- Hikma acquires ANDA for trametinib from Novugen (April 17, 2025)
- Granules India acquires Senn Chemicals AG (April 11, 2025)
- Premier Biotech acquires OraSure's testing line (April 10, 2025)
Who to call at Curium Pharma, and when
When Curium Pharma changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Curium Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Curium Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Curium Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Curium Pharma makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Eczacıbaşı-Monrol Nuclear Product (Monrol)?
Eczacıbaşı-Monrol Nuclear Product (Monrol) was acquired by Curium Pharma, based in Paris. The deal was reported on March 28, 2025. Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Curium Pharma is privately held and operates in Manufacturing.
When did Curium Pharma acquire Eczacıbaşı-Monrol Nuclear Product (Monrol)?
Curium Pharma's acquisition of Eczacıbaşı-Monrol Nuclear Product (Monrol) was reported on March 28, 2025. Curium Pharma has completed the acquisition of Eczacıbaşı-Monrol Nuclear Products Co. This acquisition enhances Curium's manufacturing capacity for Lutetium-177, expands its geographical footprint, and adds significant R&D capabilities. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Eczacıbaşı-Monrol Nuclear Product (Monrol) do?
Eczacıbaşı-Monrol is a dedicated specialist in nuclear medicine with extensive manufacturing and logistics infrastructure in Istanbul, Turkey. It is privately held, operating in Manufacturing, and is based in Istanbul.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.